
Born in Bosnia-Herzegovina, grew up in Boston, now Assistant Prof hematology/HSCT @CityofHopeOC in Irvine, CA | alum of @UMASSChan @StephensonCC
Irvine, CA
Joined October 2019
- Tweets264
- Following438
- Followers279
- Likes1.1K
Azra Borogovac retweeted
#Hematology Fixed-duration epcoritamab plus R-CHOP for newly diagnosed LBCL #lymphoma with an IPI score of 3 to 5: results from the EPCORE NHL-2 trial #lymsm
ashpublications.org/blood/ar…
Excited to serve as faculty at the #ICETCongress where I’ll be debating bispecific vs CART with @MediHumdani Especially looking forward to catching up with old friends and colleagues from @StephensonCC! Thanks to @Taha_CancerDoc and rest of the organizers for the invite!
📣 It’s official! Meet the 28 speakers, moderators, and panelists for the National ICE-T Congress in Oklahoma City on January 30, 2027.
Join us for live debates in myeloma, lymphoma, and myeloid disease. Swipe to meet the faculty. See you in OKC! 👇
#ICETCongress #CellularTherapy
@kczmj @Taha_CancerDoc @msalmanfaisal @Larvol @OpenMedKate @YLeyfman @zarabaloc @CancerNetwrk @oncodaily @US_HMC @USMIRCNEWS @Maho_VuMedi_Hem @VuMediHemOnc @CurrentOncology
Azra Borogovac retweeted
Please mark your calendar and join us here in OKC to engage in patient-centered evidence based conversations on the most recent developments in the treatment of patients with hematologic malignancies, thank you to all the speakers and to our ICE-T and KU partners
📣 It’s official! Meet the 28 speakers, moderators, and panelists for the National ICE-T Congress in Oklahoma City on January 30, 2027.
Join us for live debates in myeloma, lymphoma, and myeloid disease. Swipe to meet the faculty. See you in OKC! 👇
#ICETCongress #CellularTherapy
@kczmj @Taha_CancerDoc @msalmanfaisal @Larvol @OpenMedKate @YLeyfman @zarabaloc @CancerNetwrk @oncodaily @US_HMC @USMIRCNEWS @Maho_VuMedi_Hem @VuMediHemOnc @CurrentOncology
Azra Borogovac retweeted
Save the date, Oklahoma City! 📅 The ICE-T Congress is coming to OKC on January 30, 2027. Join us to explore what’s next in cellular therapy and share ideas for bringing these treatments to more patients. See you in OKC! #ICETCongress #CellularTherapy @Taha_CancerDoc
Azra Borogovac retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
The MMRF Walk is coming up, and I'm walking to cure multiple myeloma. Every dollar helps—will you help me reach my fundraising goal? do.nr/8oii8ctc
Azra Borogovac retweeted
#Glofitamab with #polatuzumab vedotin in relapsed/refractory CNS #lymphoma: retrospective single-institution series, n=9, including chemorefractory Burkitt #lymphoma and TP53-mutant mantle cell #lymphoma.
ORR 100%, CR 89%. Responses in both brain parenchymal and leptomeningeal disease, with flow cytometry showing clearance of #lymphoma cells from CSF within days of treatment.
n=9, retrospective, short follow-up... so this is a signal rather than proof but enough to justify more evaluation in trials.
#CNSL #lymphoma
#lymsm
doi.org/10.1182/bloodadvance…
Azra Borogovac retweeted
Oh how lucky we are to be able to live this and feel this!❤️🇧🇦⚜️ #FIFAWorldCup
Azra Borogovac retweeted
Fantastic talk by @AbhiTrip87 at @AUC3_Official. Terrific insights into contemporary management of IO-refractory advanced #bladdercancer - a complicated space indeed. All star panel with @jackiebrown_MD, @MichvdHeijden, @bergsa83, @DanielPetrylak & @tompowles1. Proud to see both he & @WesleyYipMD representing @cityofhope so well - many thx to @DrRanaMcKay & @DrChoueiri for the opportunity!
Azra Borogovac retweeted
Replying to @bdermanmd
@bdermanmd MRD based stopping maintenance
- makes a strong case for stopping in MRD neg- sustained MRD neg, no HR features, PET neg
- but we should and can stop earlier with effective Rx. we should think about this more
#ASH25
Azra Borogovac retweeted
Safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel) in Relapsed/Refractory multiple myeloma (RRMM) [Nov 3, 2025] @AzraBoro88 et al. #ASH25 abs25-12050
submit.hematology.org/progra… #mmsm #CARTcell n=40
Azra Borogovac retweeted
Replying to @cityofhopeoc
@cityofhopeoc :
it’s a FACT we are doing HCT thanks to this great team
Azra Borogovac retweeted
Very honored to have received the @PCF_Science Young Investigator Award!
Incredibly grateful for my mentorship team led by @TDorffOnc! Also thankful for all my current and past mentors/teachers for the support.
@cityofhope @cityofhopeoc
Azra Borogovac retweeted
Honored to share our newly published manuscript ascopubs.org/journal/jco which demonstrates that circulating tumor DNA (ctDNA) by PhasED-Seq offers the most precise definition of remission after frontline therapy for patients with large B-cell lymphoma (LBCL) out now in @JCO_ASCO. #ctDNA detection of #MRD. 1/18 – at Stanford, CA
Azra Borogovac retweeted
The SUNMO trial manuscript is now published at @JCO_ASCO! Mosun-Pola is superior to RGemOx in patients with ref/rel LBCL with 3X progression free survival and 2x complete response rates. Only 4% had CRS more than a fever. #lymsm
@elizabeth_budde
ascopubs.org/doi/10.1200/JCO…
Azra Borogovac retweeted
Treatment can be difficult, and everyone finds something that helps them get through. For grateful patient Ray Hartjen, it’s music. Listening, composing and playing takes him to a place of peace, even on the hardest days, and reminds him there is still beauty, light, and hope. 💙
Azra Borogovac retweeted
Replying to @DoctorAKrishnan
@DoctorAKrishnan is an amazing mentor, colleague and a leader of the City of Hope Myeloma @cityofhopeoc program and a national leader. Very pleased she is the SWOG chair and looking forward to the collaboration.
So proud of @DoctorAKrishnan who was just announced by @SWOGChair as chair of the @SWOG Barlogie-Salmon Myeloma Committee, taking over for @Myeloma_Doc. I’ve know Dr. Krishnan for 2 decades - you won’t find someone more perfect for this role! #SWOGonc
Azra Borogovac retweeted
Incredibly grateful to the mentorship and support from entire @eaonc #GU team @ChrisSweens1 @cityofhope @CityofHope_GU @montypal @DrRaviSalgia @TDorffOnc
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
buff.ly/FuH8fhx
The 10-year follow-up of the CHAARTED trial confirms that adding docetaxel to androgen deprivation therapy significantly improves overall survival in patients with high-volume metastatic hormone-sensitive prostate cancer, while PSA nadir <0.2 ng/mL at 6 months emerged as a powerful independent predictor of long-term survival across both treatment arms.
Achieving this low PSA was strongly associated with better outcomes regardless of baseline prognostic factors, and docetaxel increased the likelihood of reaching this threshold, supporting the use of PSA nadir as a key marker for response assessment and potential response-adapted treatment strategies. #ProstateCancer
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas
@DrYukselUrun
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua
Azra Borogovac retweeted
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
buff.ly/FuH8fhx
The 10-year follow-up of the CHAARTED trial confirms that adding docetaxel to androgen deprivation therapy significantly improves overall survival in patients with high-volume metastatic hormone-sensitive prostate cancer, while PSA nadir <0.2 ng/mL at 6 months emerged as a powerful independent predictor of long-term survival across both treatment arms.
Achieving this low PSA was strongly associated with better outcomes regardless of baseline prognostic factors, and docetaxel increased the likelihood of reaching this threshold, supporting the use of PSA nadir as a key marker for response assessment and potential response-adapted treatment strategies. #ProstateCancer
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas
@DrYukselUrun
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua





































